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The liver is one of the richest organs in terms of number and density of mitochondria. Most chronic liver diseases are associated
with the accumulation of damaged mitochondria. Hepatic mitochondria have unique features compared to other organs’
mitochondria, since they are the hub that integrates hepatic metabolism of carbohydrates, lipids and proteins. Mitochondria
are also essential in hepatocyte survival as mediator of apoptosis and necrosis. Hepatocytes have developed diﬀerent mechanisms
to keep mitochondrial integrity or to prevent the eﬀects of mitochondrial lesions, in particular regulating organelle biogenesis
and degradation. In this paper, we will focus on the role of mitochondria in liver physiology, such as hepatic metabolism, reactive
oxygen species homeostasis and cell survival. We will also focus on chronic liver pathologies, especially those linked to alcohol,
virus, drugs or metabolic syndrome and we will discuss how mitochondria could provide a promising therapeutic target in these
contexts.
1.Introduction
Mitochondria are intracellular double membrane-bound
structures that provide energy (ATP) for intracellular
metabolism. The intramitochondrial metabolism includes
Krebs cycle and beta-oxidation. Mitochondria are also
essential for assembly of iron sulfur clusters and regulation
of calcium homeostasis. However, mitochondria are not
only the cell’s powerhouse, organelles whose particular
architecture and biochemical composition enable the maxi-
mization of energy production by oxidative phosphorylation
(OXPHOS), but they also have a second crucial function,
namely, the control of cell death following activation of
intracellular signaling cascades or death receptor-mediated
pathways [1]. Indeed, the mitochondrial membrane per-
meabilization (MMP) is the decisive event that marks the
transition from survival to death. Thus, mitochondrial
membranes integrate proapoptotic and antiapoptotic signals
coming from microenvironment or from other intracellular
organelles, such as endoplasmic reticulum or lysosomes,
deﬁning the ultimate cell fate [1, 2]. The number and
functions of mitochondria can vary depending on age, sex,
organ, and physiological or pathological conditions that are
still unknown [3–5].
Mitochondrial dysfunctions are frequently described as
early and initiating events in various chronic pathological
conditions in diﬀerent tissues and organs, such as liver,
brain, or heart [6–8].Most forms ofchronic liver diseases are
associated with the accumulation of damaged mitochondria
responsible for abnormal reactive oxygen species (ROS)
formation, glutathione (GSH) depletion, protein alkylation,
and respiratory complex alterations. Depending on their
nature and severity, the mitochondrial alterations may
induce lipid accumulation, apoptosis, and/or necrosis2 Biochemistry Research International
leading to hepatic cytolysis and inﬂammation. These
pathological events can correspond to diﬀerent clinical
features, such as lactacidosis, hypoglycemia, elevated serum
transaminases, higher conjugated bilirubinemia, and hyper-
ammonemia. However, a growing body of literature has also
shown that demised cells with damaged mitochondria can
develop cytoprotective mechanisms to ensure cellular energy
homeostasis and limit cell death [9–12]. These mechanisms
consist in both activation of intracellular pathways targeting
mitochondria function and intercellular and interorgan
signaling to coordinate adaptive metabolic responses within
theorganismasawhole.Theregulationofthemitochondrial
biogenesis and/or turnover (by general autophagy or speciﬁc
mitochondria-targeted mitophagy) plays an important role
in the balance of cell survival and cell death [13]. This
balance is importantly linked to the energy metabolism
homeostasis, in particular with ATP synthesis, as it has been
reported in some chronic liver pathologies, such as steatosis
and nonalcoholic steatohepatitis (NASH) [14].
In this paper, we will focus on the role of mitochondria
in liver physiology and pathologies, especially those linked
to alcohol, virus, drugs, or metabolic syndrome and we
will discuss how mitochondria could provide a promising
therapeutic target in these contexts.
2.MitochondriainLiverPhysiology
The liver is one of the richest organs in terms of number
and density of mitochondria. The density of mitochondria
is diﬀerent in various tissues depending upon numerous
factors, mostly the demands of oxidative phosphorylation.
A study showed that in nontumorous liver tissue the copy
number of mitochondrial DNA (mtDNA) in male patients
aﬀected by hepatocellular carcinoma (HCC) was lower than
thatofthefemalepatients(5308±484versus8027±969, P<
0.05) [4]. Since each mitochondrion can host from two to
t e nc o p i e so fm t D N A[ 5], we can assume that in the liver, the
number of mitochondria could range from 500 to 4000 per
hepatocyte.
In this chapter, we will review the role of mitochondria
in hepatic metabolism, reactive oxygen species (ROS) home-
ostasis, and cell death regulation.
2.1. Mitochondria Are Essential in the Hepatic Metabolism.
The liver is an essential life organ in all mammals and plays
a central role in the homeostasis of carbohydrate, lipid, and
protein metabolism of the organism. The liver is a main
target of insulin and glucagon signaling and contributes
to balancing glucose blood levels by regulating glycogen
synthesis and gluconeogenesis in hepatocytes [15]. It is also
a key organ in maintaining lipid homeostasis: it is the main
site of fatty acid oxidation together with the muscle (mainly
β-oxidation taking place into the mitochondria) and it is
the sole organ able to synthesize fatty acids by de novo
lipogenesis [16]. Finally, the liver is a key regulator of protein
metabolismfortheentireorganismashepatocytessynthesize
essentialproteinssuchasalbuminandlipoproteinsandallow
ammonia detoxiﬁcation through the urea cycle [17].
In this context, the mitochondria provide the hub that
integrates these pathways, serving as a critical site for
the production and exchange of metabolic intermediates
(Figure 1). It plays a critical role in orchestrating these
complex metabolic networks in order to maintain proper
homeostasis.
Mitochondriaarelargelyinvolvedinglucosemetabolism,
as the pyruvate dehydrogenase (PDH) complex is expressed
in the mitochondrial matrix. It is composed by 5 sub-
units (pyruvate dehydrogenase, E1 alpha and E1 beta;
dihydrolipoamide S-acetyl transferase, E2; and lipoamide
dehydrogenase, E3 and E3BP). It catalyzes the conversion of
pyruvate, the last metabolite of aerobic glycolysis, to Acetyl-
CoA and CO2. In the last ten years evidence has accumulated
showing an important involvement of liver mitochondria
in insulin resistance. In insulin resistant states, alterations
in mitochondrial function, structure, and organization have
been described [18]. In particular, a decrease in respiration
and ATP production has been frequently described and
the decreased eﬃciency is often attributed to excessive
mitochondrial ROS production inducing respiratory chain
protein oxidation [14, 18, 19].
Concerning lipid metabolism, few mitochondrial pro-
teins play key roles in catabolism as well as in anabolism.
The carnitine palmityl transferases I and II (CPT I-II) are
expressed at the mitochondrial outer membrane (MOM)
and mitochondrial inner membrane (MIM), respectively,
and are essential for acyl-CoA transport and subsequent
fatty acid β-oxidation in liver and muscle. A mitochondrial
transport protein, the citrate transport protein (CTP), allows
acetyl-CoA to be transported from mitochondria to the
cytosol in the form of citrate in order to be used as
building block in hepatic de novo lipogenesis [20]. Hepatic
mitochondria are essential also in protein metabolism.
Nitrogen enters the liver as free ammonia and amino acids,
mostly glutamine and alanine [17]. Enzymes involved in
ammonia detoxiﬁcation and urea synthesis (glutamate dehy-
drogenase, carbamoyl phosphate synthetase I and ornithine
transcarbamylase)areexclusivelyexpressedinthehepatocyte
mitochondria. Indeed, the ﬁrst step in the urea cycle for
ammonia detoxiﬁcation and disposal is located at mito-
chondria and mediated by the enzyme carbamoyl phos-
phate synthetase 1 (CPSI). CPSI is allosterically regulated
by cytosolic N-acetyl-L-glutamate (NAG) [21]. Ammonia
can be also converted to glutamine by the glutamine
synthetase (GS) catalyzing the condensation of glutamate
and ammonia and, vice versa, ammonia can be generated
by glutaminase. Therefore, an increase in blood ammonia
depends on the activity of the enzyme glutamine synthetase,
the glutamine/glutamate cycle, and the tissue capacity to
eliminate toxic ammonia. Mitochondria represent a major
site of glutamine metabolism, as both glutaminase and GS
are mitochondrial processes in the liver. Interestingly, in
absence of glucose but with high glutamine concentrations,
mitochondrial structure and dynamics change towards a
more condensed conﬁguration and extended reticulum [22].
Moreover, urea and glutamine metabolism are diﬀerently
distributed in the hepatic acinus. Ammonia is taken up by
periportalhepatocytes,metabolizedtoureaviatheureacycleBiochemistry Research International 3
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Figure 1: The role of hepatocyte mitochondria in liver metabolism. The liver is a central organ for the homeostasis of carbohydrates,
lipids and proteins metabolism. In this context, hepatocyte mitochondria are essential in regulating the ﬂux of metabolites in the cell in
order to adjust energetic demand, ammonia detoxiﬁcation, or anabolic pathways. Energy demand is met by complete oxidation of acetyl
groups coming from glycolysis through tricarboxyilic acid cycle or of acyl groups coming from lipolysis through β-oxidation. Moreover,
mitochondria are a unique site for metabolizing ammonia into the less toxic urea. Then, mitochondria provide shuttle proteins that allow
speciﬁc addressing to anabolic pathways, as in the case of citrate transport protein (CTP) (see text for details).
and excreted through the kidneys. Any ammonia escaping
detoxiﬁcation is usually trapped by perivenous hepatocytes,
where it is converted to glutamine via glutamine synthetase
[23]. Indeed, urea synthesis enzymes and glutaminase are
expressed in periportal hepatocytes, while glutamine syn-
thetase is expressed in perivenous hepatocytes [17]. Then,
the periportal region has a low aﬃnity but a high capacity
for ammonia detoxiﬁcation. Hepatic GS allows ammonia
scavenging, and when liver impairment is present, a dimin-
ished detoxiﬁcation capacity is observed. GS has a short half-
life and its activity is regulated and modulated by several
mediatorsandhormones.Thebrainalsousesglutaminesyn-
thesis for metabolizing ammonia and for deamination in the
presynaptic terminals to produce glutamate, an important
excitatory neurotransmitter. When it accumulates, it is taken
up by the astrocytes and recycled back to glutamine, the
“storage centre” for free ammonia [24, 25]. It is interesting
to note that the diﬀerent subcellular localization of GS
(mitochondrialinhepatocytesandcytoplasmicinastrocytes)
has been considered a partial explanation to the higher
toxicity of ammonia in the brain than in the liver [26].
However, the exact role of mitochondrial dysfunctions in
hyperammonemia still needs to be addressed, in particular
for chronic liver disease. However, liver and mitochondria
metabolism are directly involved in the homeostatic balance
of brain ammonia, glutamine, and glutamate.
2.2. Mitochondria Are Essential in Reactive Oxygen Species
Homeostasis. Mitochondria are the intracellular organelles
devolved to energy (ATP) production in all eukaryotic cells
through oxidative phosphorylation (OXPHOS). OXPHOS
is allowed by the four multiprotein complexes of the mito-
chondrial respiratory chain (MRC) and by the ATP synthase.
OXPHOS physiologically produces reactive oxygen species
(ROS) and in vitro estimations lead to considering that up to
2% of oxygen consumption results in superoxide anion gen-
eration [27]. Thus, mitochondria are a main source of ROS
(Figure 2). ROS are produced during oxidative metabolism
mainlybythecomplexesI,III,orIVoftheelectrontransport
chain, where electrons can prematurely reduce oxygen,
resulting in the formation of superoxide radical [27–30]. In
the normal state, most of the ROS generated by the MRC are
detoxiﬁed by the mitochondrial antioxidant enzymes, such
as SOD2/MnSOD, which convert superoxide to hydrogen
peroxide, subsequently detoxiﬁed by GSH peroxidase. The
remaining nondetoxiﬁed ROS diﬀuse out of mitochondria
and serve as signaling molecules vital for normal cellular
functions [31]. These physiological ROS are involved in spe-
ciﬁc cellular pathway aimed to adapt global metabolism to
transient or chronic stress conditions. It is interesting to note
that ATP synthase may also have a regulating role in ROS
production. Actually, in the experimental model of aging
providedby the fungusPodospora anserine, characterizedby
mitochondrial etiology of aging, the alpha subunit of ATP
synthasefunctionsasasensorofoxidativestressandprovides
an intramolecular quencher (at the residue Trp503) for ROS
[32].Moreover,arecentmechanismthatseemstobuﬀerROS
excess has been described in physiological and pathological
conditions. The expression of uncoupling proteins (UPCs)
promotes a controlled uncoupling of proton ﬂux from the
ATP synthase and could lead to decreased ROS production
[33].4 Biochemistry Research International
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Figure 2: The role of hepatocyte mitochondria in reactive oxygen species homeostasis. Mitochondria are a physiological source of reactive
oxygenspecies(ROS).Inthiscontext,ROSexertasignalingroleincellproliferationanddiﬀerentiation.However,diﬀerenttypesofstresscan
target directly or indirectly hepatocyte mitochondria, such as drugs, virus, hypoxia, inﬂammatory cytokines, excess of β-oxidation, ectopic
expression of cytochromes P450. In this case, overproduction of ROS may damage both mitochondrial and other cellular components, such
as OXPHOS protein subunits, lipid membranes, mitochondrial, or nuclear DNA. These cellular lesions can favor the development of tissue
lesions, such as steatohepatitis or hepatocellular carcinoma.
2.3. Mitochondria Are Essential in Cell Survival. Mitochon-
driaaretheessentialactorinkeepingthebalancebetweencell
survival and cell death, in particular in hepatocytes, where
they trigger the intrinsic pathway of apoptosis and are also
involved in necrotic cell death. The regulation of membrane
permeability is the main mechanism that makes the cells
shift from survival to cell death. The MOM is permeable
to solutes of molecular mass (MM) ≈ 6kDa due to the
presence of channels, such as the voltage-dependent anion
channel (VDAC), which belongs to the porin subfamily.
However, with an estimated pore diameter about 2.6–3nm,
VDAC would not allow the passage of a folded protein
like cytochrome c. In contrast, the MIM is almost totally
impermeable and transport of ions and solutes is granted by
mitochondrial carrier proteins. Most mitochondrial proteins
exhibit dual functions, a vital metabolic function, and a
lethal pro-apoptotic function. This applies to various chan-
nels: voltage-dependent anion channel (VDAC), adenine
nucleotide translocase (ANT), Bax, t-Bid, Bak; receptors
(e.g., TOM22); chaperones (cyclophilin D, CypD), as well as
oxidoreductases (apoptosis-inducing factor, AIF).
During apoptosis, many signals can converge to the
mitochondrion to MMP, the rate-limiting step in the exe-
cution of the death process [1]. MMP is regulated mainly
by the members of Bcl-2 family, members of the PTP
complex (VDAC, ANT, CypD) and lipids [1]. Bcl-2 family
is composed of pro-apoptotic proteins (e.g., Bax, Bak, Bid,
Bik, Bnip3) and anti-apoptotic members (Bcl-2, Bcl-xL,
Bcl-w, Mcl-1, A1). Pro-apoptotic proteins favor MMP by
translocating to MOM and forming mega channels, mainly
by oligomerization (e.g., Bax-Bak oligomers or Bax-VDAC
complexes), while anti-apoptotic members stabilize MOM
a n dt e n dt op r e v e n tM M P[ 1, 34–36]. Accumulation of
modiﬁed lipids (e.g., oxidized cardiolipin, ceramide) and
ions (e.g., Ca2+) in the mitochondrion can also inﬂuence
MMP [37]. Moreover, the intracellular milieu, such as pH,
ROS, and ATP levels can contribute to deﬁne a permissive
environment for MMP execution [1]. Multiple mechanisms
can mediate MMP, depending on the cell type and the
death stimuli. They can aﬀect either the MOM, or both
mitochondrial membranes (MOM+MIM). In the MOM
model, intermembrane space proteins are released into the
cytosol by passage through large proteic/lipidic channels
while, in the MOM+MIM model, intermembrane space
proteins are freely released into the cytosol through the
MOM ruptures. Nevertheless, these two models can coexist
in conditions involving on the one hand the translocation
of the truncated form of Bid (tBid) to mitochondria, and in
the other hand mitochondrial Ca2+ accumulation and ROS
increase, as observed in conditions of endoplasmic reticulum
stress [1]. In the MOM+MIM model, the contribution of
the permeability transition pore (PTP) seems to play an
important role. The PTP consists of a multiprotein complex
(PTPC) and various proteins are involved in its opening.
Long lasting opening of PTPC increases MIM permeability
and, in the presence of adequate amounts of ATP, wouldBiochemistry Research International 5
lead to apoptotic cell death [1]. PTPC opening is highly
sensitive to Ca2+, prooxidant agents, pro-apoptotic Bcl-2
family members and some chemotherapeutics agents [38].
However, Ca2+-induced PTP opening has been also reported
to induce necrotic cell death, in particular when intracellular
ATP levels are too low to allow apoptosis execution [39].
Once initiated, MMP leads to the release into the
cytosol of caspase-dependent proteins (i.e., cytochrome c or
Smac/DIABLO) and caspase-independent proteins (such as
apoptosis-inducing factor, AIF, or EndoG) with consequent
coordinated cell degradation [40]. Concomitantly, MMP
provokes a mitochondrial failure with dissipation of the
inner membrane potential (ΔΨm), subsequent arrest of
OXPHOS and ATP synthesis, and increased ROS level.
Therefore, MMP constitutes a point of no return of the
activation cascade of cell death [41].
3.MitochondriainLiverPathology
Most liver pathologies, including alcoholic liver disease,
nonalcoholic fatty liver disease (NAFLD) and nonalco-
holic steatohepatitis (NASH), drug-induced hepatotoxicity,
viral hepatitis, and HCC, are characterized by mitochon-
drial dysfunctions. Moreover, during liver surgery, liver
cells, in particular hepatocytes and endothelial cells suﬀer
ischemia/reperfusion (I/R) injury. In the liver, as well
a si no t h e ro r g a n ss u c ha sb r a i na n dh e a r t ,I /R injury
involved mitochondrial permeability transition [1]. Since
these abnormalities aﬀect all the aforementioned physiolog-
ical functions of mitochondria, we will review their roles in
liver pathologies with a particular focus on the aspects of cell
death regulation, alteration of hepatocyte metabolism, and
disruption of ROS homeostasis.
3.1. Mitochondria in Cell Death Regulation. Mitochondria
are key organelles in the development of liver diseases char-
acterized by hepatocyte death and subsequent inﬂammation
(Figure 3). Actually, increased hepatocyte apoptosis has been
correlated with inﬂammation, ﬁbrosis, and cell turnover,
conditions that are permissive for the development of HCC
[2]. Hepatocyte mitochondria are essential in making eﬀec-
tive the extrinsic pathway activated by many ligands, such as
Fas, TRAIL or TNF-α [2]. Moreover, constitutive expression
of both anti-apoptotic proteins Bcl-xL and Mcl-1, belonging
to the Bcl-2 family, is required to avoid spontaneous caspase
3/7 activation, suggesting essential cytoprotective functions
of these proteins in the hepatocyte [42, 43]. Bcl-2 is not
constitutively expressed in the liver; however, it can be
induced in order to cope with I/R, as shown in ischemic
preconditioning during partial hepatectomy [44, 45].
Fas- and TRAIL-mediated apoptosis are involved in
viral hepatitis, playing a crucial role in the elimination of
infected cells and the hepatitis viral core protein binds Mcl-
1 impairing its cytoprotective function [46–48]. TNF-α is
secreted by inﬁltrating cytotoxic T lymphocytes during HBV
infection and its apoptotic eﬀect seems to be mediated by
HBVx protein [2]. Mitochondrial apoptosis is also involved
in the pathogenesis of NAFLD and in NASH [15]. In an
experimental model using mice fed with a methionine and
choline deﬁcient diet, apoptosis was induced by an increase
hepatic expression of functional p53, with a concomitant
increase in the cleavage of Bid to tBid and a decrease
expressionofBcl-xL [49].Moreover,p53wasalsoresponsible
forTRAILreceptorexpression,linkingintrinsicandextrinsic
apoptosis pathway in NASH [49]. Recently, saturated free
fatty acids have been shown to activate the proapoptotic
proteins Bim and Bax via JNK, thus inducing MMP, and also
increase ROS production [50].
Hepatocyte necrosis is usually considered an acciden-
tal (nonprogrammed) form of cell death, resulting from
metabolic failure and consequent rapid ATP depletion [51].
It has been ﬁrstly described during I/R injury following
liver transplantation or hepatectomy, but it is also described
in NASH. In fact, hepatocytes necrosis is associated with
signiﬁcant inﬂammatory response, due to the liberation
of IL1-β,T N F - α and other newly described proinﬂamma-
tory proteins, namely, damage-associated molecular-pattern
(DAMP) molecules, such as HMGB1, that activate innate
immunity response, such liver resident macrophages (Kupf-
fer cells) and polymorphonuclear cells [45, 51–54]. Recently,
accumulated evidence indicates that necrosis can also occur
in a regulated manner and that the liberation of cytokines
from dying cells can function as a sentinel signal alerting
to the need for defensive response [51]. This regulated or
programmed necrosis (necroptosis) is initiated by death
receptors, like apoptosis, but requires activation of speciﬁc
kinases (receptor interacting proteins 1 and 3) and its
executioninvolvestheactivedisintegrationofmitochondrial,
lysosomal, and plasma membranes [55]. Interestingly, in
the context of I/R injury, the PTPC opening seems to be
a common event anticipating both necrotic cell death and
apoptosis, reinforcing the idea that programmed necrosis
may be involved in clinical and pathological contexts. In
an experimental model of orthotopic liver transplantation
in rats, inhibition of PTP by cyclosporine A or acidic pH
improved mitochondrial and hepatocellular functions, in
particular decreasing the percentage of apoptotic cells but
not of necrotic cells [56, 57]. These results seem to conﬁrm
the concept that apoptosis is typically an early event in
hepatocyte injury. Importantly, in steatotic livers submitted
to ischemia/reperfusion, necrosis is predominant compared
with normal liver in which apoptosis is the main form
of cell death [52, 53]. This diﬀerence has been partially
linkedtothemetabolic/energeticdiﬀerencebetweensteatotic
livers and normal liver [52] since fatty liver mitochondria
have a decreased content of cytochromes c oxidase, produce
superoxide anion and H2O2 at increased rate and have an
increase content in UPC-2 compared with normal livers,
resulting in decreased ATP production that aﬀects apoptosis
execution, and favors necrosis [58].
3.2. Mitochondria in Alteration of Hepatocyte Metabolism.
The aforementioned data suggest that mitochondria may be
the convergence point between various metabolic stresses
and cell death in hepatocyte. In this context, it merits
noting that the cytosolic glucokinase, or hexokinase IV, the6 Biochemistry Research International
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Figure 3: The mitochondria are central organelles in determining cell fate in liver diseases. Hepatocyte cell death is common to many liver
diseases. Diﬀerent stress stimuli can induce death signaling, such as toxic free fatty acids, DNA damage, endoplasmic reticulum (ER) stress
observed in metabolic disease. In these contexts, mitochondria are essential to determine cell fate, as in hepatocyte the activation of the
intrinsic pathway of apoptosis by cell death receptors is not usually suﬃcient to induce cell death and liberation of proapoptotic factors from
mitochondria is a mostly necessary event. Moreover, previous alterations of mitochondrial function causing decreased ATP synthesis can
induce a shift from apoptotic to necrotic cell death.
hepatic/pancreatic isoform of hexokinase, has been recently
reported to be associated to mitochondrial proteins, such
as Bad, at the MOM [59, 60]. The association of the pro-
apoptotic protein Bad with the glucokinase suggests that
a close integration exists between the pathways of glucose
metabolism and apoptosis [59].
Many studies on obese, diabetic, or NASH patients
have shown functional and structural abnormalities in
hepatocyte mitochondria, such as OXPHOS impairment
or megamitochondria [61]. Interestingly, both increased or
decreased β-oxidation in insulin resistant hepatocytes has
been reported as characteristic of liver steatosis and insulin
resistance [16, 62, 63]. Decrease in β-oxidation activity
induces diacylglycerol (DAG) accumulation and steatosis in
the hepatocyte with concurrent activation of PKC pathway
and inhibition of insulin signaling [62]. In insulin-resistant
patients an increased activity of hepatic β-oxidation was
observed and this was correlated to an increase in ROS
production [61, 64]. Elevated β-oxidation could be an
adaptive mechanism to limit free fatty acid lipotoxicity, thus
providing large amounts of reduced equivalents (NADH)
regardless of energetic requirements ﬁnally promoting ROS
production due to impairment of respiratory chain [18].
These results linked mitochondrial metabolic dysfunctions
to oxidative stress due to increased ROS production.
3.3. Mitochondria in Disruption of ROS Homeostasis. In-
creased ROS production has been described in most liver
pathologies. Augmented generation of mitochondrial ROS
has been reported in various animal models of NASH,
namely, genetically obese-diabetic ob/ob mice [58]a n dr a t sBiochemistry Research International 7
fed with a choline-deﬁcient diet [65]. Moreover, mito-
chondria can be an ectopic site of cytochromes P450 2E1
expression [61, 66], where it can produce ROS and induce
lipid peroxidation, as shown in the liver of an experimental
model of diabetic rat [67].
Mitochondrial dysfunctions and ROS generation have
been clearly shown in alcoholic liver disease [68]. Exces-
sive ethanol consumption perturbs sinusoidal blood ﬂow,
inducing ischemia regions, and causes increased production
of TNF-α, which induces inﬂammatory cell inﬁltration and
an increase in hepatic O2 consumption [69, 70]. Chronic
ethanol consumption induces profound disruption in mito-
chondrial metabolism, in particular decreasing the rate of
ATP synthesis, thus placing hepatocytes under bioenergetic
stress [68]. Under alcohol feeding, mitochondria contribute
to the production of ROS in hepatocytes through various
mechanisms. Ethanol metabolism increases the availability
of NADH, resulting in a more reduced state of complexes I
and III of the respiratory chain with a consequent increased
probability of superoxide ion production [71]. Moreover,
chronic alcohol consumption decreases mitochondrial pro-
tein synthesis mainly due to alcohol-mediated damage
to mtDNA, contributing to decreased functioning of the
oxidative phosphorylation system [72–74].
Mitochondrial ROS also play an important role in
viral hepatitis. HCV core protein directly interacts with
mitochondria and inhibits complex I activity, inducing
an increased production of mitochondrial ROS, reducing
threshold for Ca2+ and ROS-induced MMP [75]. Moreover,
it has been recently shown that during HBV infection,
HBx protein interacts with mitochondria, increasing ROS
production [76]. The increase in ROS production was nec-
essary, although insuﬃcient, to induce the proinﬂammatory
enzyme cyclooxygenase 2 (COX-2), linking mitochondrial
dysfunction with liver inﬂammation in HBV infection [76].
Numerous investigations have shown that mitochondrial
dysfunction is a major mechanism of drug- (or drug-
metabolite-) induced liver injury [77]. Diﬀerent mecha-
nisms of mitochondrial dysfunction have been described
in drug-induced hepatotoxicity, including membrane per-
meabilization, OXPHOS impairment, inhibition of fatty
acid oxidation, and mtDNA depletion, and it appears that
overproduction of reactive oxygen species by the damaged
mitochondria could play a major role [77]. Finally, there
is evidence showing a role of ROS in hepatocarcinogenesis
[78]. Chemical hepatocarcinogens, such as the mycotoxin
aﬂatoxin B1 and 2-acetylaminoﬂuorene (2-AAF), induced
increased ROS production in hepatocytes. In particular, 2-
AAF altered mitochondrial redox cycling and it activated
NADPH oxidase, an important ROS producing enzyme,
through PI3K/Akt pathway [79–81]. Growth factors and
activated oncogenes also induce ROS overproduction. Cul-
tured cells treated with epidermal growth factor (EGF) and
platelet-derived growth factor (PDGF) showed increased
levels of H2O2 [82, 83]. Double transgenic mice bearing
liver-targeted expression of transforming growth factor
and the oncogene c-myc develop HCC as early as 4
and 8 months of age and elevated ROS levels associ-
ated with lipid peroxidation, mitochondrial damage and
decreased GSH were already observed at 2-3 months of age
[84].
Thus, it is clear that even a mild dysfunction of mi-
tochondria in the liver could lead to hepatic and systemic
pathological conditions and the identiﬁcation of type and
timing of mitochondrial lesions could allow major ad-
vancement in prevention, early diagnosis and treatment of
systemic and liver diseases.
4. Mitochondria in the Cytoprotection of
Damaged LiverCells to EnsureHomeostasis
inChronicLiverDiseases
Mitochondrial dysfunction is described in various hepatic
diseases or lesions, such as NAFLD, I/R injury, drug toxicity
or hepatocellular carcinoma, and it is often detected as
an early alteration, suggesting its causative eﬀect [6, 85–
87]. Cells have developed diﬀerent mechanisms to keep
mitochondrial integrity or to prevent the eﬀects of mito-
chondrial lesions, such as disposal of damaged mitochondria
by autophagy/mitophagy, increased biogenesis of mitochon-
dria or regulation of signaling pathways to ensure energy
metabolism and limit cell death and inﬂammatory response.
4.1. Increased Biogenesis of Mitochondria. Regulation of
mitochondria biogenesis is one of the mechanisms devel-
oped by cells to keep mitochondrial integrity or to pre-
vent the eﬀects of mitochondrial lesions. The peroxisome
proliferator-activated receptor gamma coactivator-1 alpha
(PGC-1 alpha) belongs to the family of PGC-1 transcrip-
tional coactivators (PGC-1 alpha, PGC-1 beta and PRC),
whichhave been shown to be masterregulators of mitochon-
drial biogenesis, and cellular energy metabolism in many
organs,includingliver[88,89].PGC-1alphaispresentatlow
but inducible levels in the liver where it also regulates most
of the metabolic pathways, including gluconeogenesis, fatty
acid β-oxidation, ketogenesis and heme biosynthesis (Figure
4)[90–93].Understressconditions,suchaslowtemperature,
fasting or energy deprivation, PGC-1 alpha is activated
both transcriptionally by cAMP response element binding
protein (CREB) and post-traductionally by AMP-activated-
protein-kinase- (AMPK-) induced phosphorylation and
SIRT1-mediated deacetylation [89]. Following PGC-1 alpha
activation, diﬀerent nuclear factors are subsequently acti-
vated. In particular, an activation of the nuclear respiratory
factors 1 and 2 (NRF-1 and NRF-2) is observed and is
followed by increased expression of multiple mitochondrial
proteins. Moreover, PGC-1 alpha activates the nuclear recep-
tors peroxisome proliferator-activated receptor alpha (PPAR
alpha) and the estrogen-related receptor alpha (ERRalpha)
both promoting the transcription of genes involved in β-
oxidation, such as medium chain acyl-CoA dehydrogenase
and carnitine palmitoyltransferase-1A (CPT-1A) [94, 95].
The absence of adequate levels of PGC-1 alpha is correlated
with mice developing fasting hypoglycemia and hepatic
steatosis, while mouse models of type 1 and type 2 diabetes
showed high hepatic levels of PGC-1 alpha [90]. However,
it has been recently shown that the diﬀerent tissue-speciﬁc8 Biochemistry Research International
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Figure 4: Mitochondria biogenesis allows tissue adaption under stress. Mitochondria biogenesis has been recently recognized as a central
pathway in the adaptation of stress conditions in the liver, such as fasting, energy deprivation, hypoxia, or alcohol consumption. Diﬀerent
signaling pathways converge on the master regulator of mitochondria biogenesis, PGC1-alpha. In particular, AMPK and PKA signaling may
activate gene transcription controlled by PGC1-alpha, while the TGF-β has been shown to inhibit PGC1-alpha-induced gene transcription.
functions of PGC-1 alpha are tightly and independently
regulated [96]. In particular, S6 kinase-1 (S6K1), activated
in the liver upon feeding, can phosphorylate PGC-1 alpha,
decreasing its capacity to turn on genes of gluconeogenesis,
while keeping the functions of activator of mitochondrial
and fatty acid oxidation genes intact [96]. S6K1, liver kinase
B1 and AMPK are key kinases in the regulation of energy
metabolism in the liver. Actually, AMPK is emerging as
a kinase that links energy metabolism to mitochondrial
function and biogenesis since components downstream of
AMPK may contribute to stabilize mitochondrial membrane
potential for hepatocyte survival, strengthening the rela-
tionship between fuel metabolism and cell survival [10].
Actually, in the liver, the activation of AMPK has been
shown to decrease gluconeogenesis and fatty acid synthesis,
to increasefatty acid oxidation and mitochondrial biogenesis
and this could be linked to PGC-1 alpha phosphorylation,
as previously observed in skeletal muscle [97, 98]. Interest-
ingly, the hepatitis B virus (HBV) uses the transcriptional
machinery involved in the hepatic response to fasting for
its own ampliﬁcation, thus HBV life cycle is under the
control of PGC-1 alpha that could be a new target for antivi-
ral therapy [99]. The dynamic changes in mitochondrial
morphology, connectivity, and subcellular distribution are
also major mechanisms in cellular homeostasis. They are
critically dependent on a highly regulated fusion and ﬁssion
machinery. Mitochondrial function, dynamics, and quality
controlarevital forthe maintenanceof tissue integrity [100].
In the liver, it has been shown that speciﬁc protection against
hepatocytemitochondrialdysfunctionplaysapreventiverole
in early stages of ﬁbrogenesis, delaying, but not avoiding, its
onset [101]. In this context, it is interesting to note that TGF-
β/Smad3 signaling pathway, known to be implicated in liver
ﬁbrogenesis, has been shown to regulate glucose and energy
homeostasis. Smad3-deﬁcient mice are protected from diet-
induced obesity and diabetes and Smad3 acts as a repressor
of PGC-1α expression, thus suggesting a link between failure
in mitochondrial biogenesis, metabolic syndrome, and liver
ﬁbrosis [102].
4.2. Autophagy and Mitophagy as Mechanisms to Limit Mito-
chondrial Lesions. A u t o p h a g yi sac e l l u l a rp a t h w a yb yw h i c h
cytoplasmic materials, including organelles, reach lysosomes
for degradation. Autophagy may occur either as a general
phenomenon, for instance, during nutrient deprivation, or
it can speciﬁcally target distinct cellular structures, such
as damaged mitochondria (mitophagy) [13]. An important
interplay exists between induction of autophagy and mito-
chondria. Actually mitochondria seem to have a key roleBiochemistry Research International 9
in general autophagy as they may supply membranes for
the biogenesis of autophagosomes during starvation [103].
Moreover, low ATP production or enhanced ROS generation
by mitochondria induces general autophagy [104, 105]. The
selective removal of mitochondria by mitophagy regulates
mitochondrial number to match metabolic demand and is
considered a form of quality control to remove damaged
mitochondria [106]. Induction of general autophagy by
a sublethal stress before a lethal stress can protect cells
against cell death [13]. Indeed, we showed that ischemic
preconditioningofliverspreviouslytreatedbychemotherapy
or steatotic livers induced autophagy and decreased necrosis
without altering apoptosis. [45, 54]. The elimination of
damaged mitochondria has been correlated to resistance of
residual mitochondria to MMP and opening of PTP, two
early events of apoptotic/necrotic cell death. This can be
explained either by the removal of mitochondria that have
a low threshold for permeabilization or by the fact that
MMP or PTP opening occurs in a fraction of mitochondria
and may activate autophagic disposal of depolarized mito-
chondria [106, 107]. Diﬀerent mechanisms may regulate
mitophagy. The dual system PINK1-Parkin is well described
especially in neural tissues. The stabilization of the kinase
PINK1occursatthesurfaceofmitochondriawithlowΔΨmito
with the subsequent recruitment of the ubiquitin ligase
Parkin and ubiquitinylation of outer membrane proteins
[108]. Mitophagy can be also stimulated by histone deacety-
lase 6, which is recruited to mitochondria and catalyzes
proautophagic cytoplasmic deacetylation reactions [109].
Interestingly, although hepatic PINK1-expression is
described [110], to our knowledge, no reports on PINK1
dependent mitophagy in the liver are published. Another
mechanism of mitophagy involves the activation of AMPK
[111]. AMPK phosphorylates and activates ULK1, one of
the initiators of autophagy and the genetic loss of AMPK
or ULK1 results in defective mitophagy in mammalian
liver and C. elegans. These ﬁndings showed a conserved
mechanism coupling nutrient status with autophagy and
cell survival [111]. Interestingly, mitochondrial degradation
by autophagy was also described in the liver of GFP-LC3
transgenic mice following nutrient deprivation, reinforcing
the results linking AMPK regulation of mitophagy [112].
4.3. Mitochondria Can Integrate Energy, Nutrient Metabolism,
and Oxidative Stress Responses Determining Cell Fate.
Insulin, secreted by pancreatic beta cells upon nutrient
stimulation, is one of the most important regulators of
nutrient utilization and metabolic homeostasis in the liver.
Insulinresistance,ahallmarkofNASHandmoregenerallyof
metabolic syndrome and type II diabetes, is accompanied by
reduction of mitochondrial OXPHOS activity and increased
ROS production [113]. On the other hand, ROS produced
during mitochondrial OXPHOS promote insulin signaling
through oxidation of insulin receptor and inhibition of
phosphatases, such as PTP1B and PTEN [113]. Importantly,
recent investigations pointed out a tight molecular crosstalk
between cell survival or cell death pathways and energy
metabolism. Using ex vivo multinuclear NMR-spectroscopy
to study metabolic pathways of [U-(13)C] glucose in mouse
liver during Fas-induced apoptosis, Gottschalk et al. found
early upregulations in glucose metabolic pathways occurred
prior to any visible signs of apoptosis, accompanied by
an increased mitochondrial energy production and cellular
glutathione synthesis [114]. This metabolic shift seems to
potentially contribute to the initiation of apoptosis by mito-
chondrial energy production and cellular glutathione stores,
thus orienting cell fate towards a less pro-inﬂammatory
death. A biochemical analysis using liver mitochondria of
two strains of mice (A/J and C57Bl/6, respectively, resistant
and susceptible to high-fat diet-induced hepatosteatosis)
conﬁrmed a rapid increase by high-fat diet feeding of the
respiration rate in A/J but not C57Bl/6 mice. Importantly,
ATPproductionwasthesameinbothtypesofmitochondria,
indicating increased uncoupling of the A/J mitochondria
[115]. These results suggest that livers can adapt to high-
fat diet feeding by increasing the activity of the oxidative
phosphorylation chain and its uncoupling to dissipate the
excess of incoming metabolic energy and to reduce the
production of ROS [115].
As we mentioned above, liver mitochondria are essential
in ammonia detoxiﬁcation following protein catabolism.
In recent years, studies from several laboratories have
uncovered a number of factors and pathways that appear
to be critically involved in the pathogenesis of hepatic
encephalopathy. Foremost is oxidative and nitrosative stress
(ONS) and the MMP playing major roles in the mechanism
of ammonia-induced astrocyte swelling [116]. The accumu-
lation of intramitochondrial glutamine has been involved.
Norenberg et al. [117] were ﬁrst to describe that the newly
synthesized glutamine could be toxic when subsequently
metabolized in mitochondria by phosphate-activated glu-
taminase,yieldingglutamateandammonia.Thus,glutamine
can be considered as a carrier of ammonia. The authors
propose to consider the intramitochondrial glutamine as
a Trojan horse that interferes with mitochondrial function
giving rise to excessive production of free radicals and
inductionoftheMPT,twophenomenaknowntobringabout
astrocyte dysfunction, including cell swelling.
Moreover, an ammonia-induced increase in intracel-
lular Ca2+ has been described which activates a number
of enzymes promoting the synthesis of reactive oxygen-
nitrogen species, including constitutive nitric oxide synthase,
NADPH oxidase and phospholipase A2. ONS subsequently
induces the opening of PTP and activates mitogen-activated
protein (MAP) kinases and the transcription factor nuclear
factor-kappaB (NF-κB). These factors act to generate addi-
tional reactive oxygen-nitrogen species, to phosphorylate
various proteins and transcription factors, and to cause
mitochondrial dysfunction [26]. The pathways and factors
described above provide attractive targets for identifying
agents potentially useful in the therapy of HE and other
hyperammonemic disorders. The most promising of them
is the glutamate/glutamine cycle. Indeed, in hyperoxia,
glutamine has been described to protect cellular struc-
tures, especially mitochondria, from damage. This has been
attributed to the activity of the tricarboxylic acid cycle
enzymealpha-ketoglutaratedehydrogenasethatwaspartially10 Biochemistry Research International
protected by its indirect substrate, glutamine, indicating a
mechanism of mitochondrial protection [118]. Glutamate
dehydrogenase (GDH), a mitochondrial enzyme linking the
Krebs cycle to the multifunctional amino acid glutamate
could be also an interesting target. Indeed, GDH controls
production and consumption of glutamate. GDH activity
is under the control of several regulators, conferring to
this enzyme energy-sensor property. Indeed, GDH directly
depends on the provision of the cofactor NADH/NAD(+),
rendering the enzyme sensitive to the redox status of the
cell. Moreover, GDH is allosterically regulated by GTP and
ADP. GDH is also regulated by ADP-ribosylation, mediated
by a member of the energy-sensor family sirtuins, namely,
SIRT4. In the brain, GDH ensures the cycling of the
neurotransmitterglutamatebetweenneuronsandastrocytes.
GDH also controls ammonia metabolism and detoxiﬁcation,
mainly in the liver and kidney. Eng and Abraham [119]
have described that ammonia, generated from Gln deam-
ination (glutaminolysis) in mitochondria, functions as an
autocrine- and/or paracrine-acting stimulator of autophagic
ﬂux. Recently, Nissim et al. [120] reported a downregulation
of hepatic urea synthesis by oxypurines. Indeed, xanthine
and uric acid, both physiologically occurring oxypurines,
inhibited the hepatic synthesis of N-acetylglutamate, the key
regulator of the ﬁrst step of mitochondrial urea cycle.
As discussed above, mitochondria are a main source
of ROS in hepatocytes and ROS importantly contribute
in liver health and disease. While ROS has been com-
monly associated to lipid, protein, and DNA oxidation
and consequent cellular damage, recent studies have shown
that mitochondria-generated ROS may be regulated and
may regulate many signaling pathways [27, 121]. Oxidative
stress may activate prosurvival pathways in hepatocytes,
such as NF-κBa n dN R F s[ 122–124]. NF-κB regulates a
complex network of pathways, as it is known to control
the transcription of over 150 genes [122]. Depending on
cell type, microenvironmental conditions and eventually
costimulated pathways, NF-κB may exert either a pro-
survivaloraproapoptotic function[122,125].Inthecontext
of hepatic oxidative stress, it has been shown that NF-κB
mayinduceantiapoptoticfactors,suchasXIAP,andfunction
like antioxidants in preventing TGF-beta 1-JNK induced-
apoptosis [126]. Moreover, NF-κB collaborates with p38
MAP kinase signaling cascade to protect hepatocytes from
liver injury induced by TNF-alpha [125].NRFs also regulates
oxidative stress response in the liver. In particular, NRF-1 has
b e e ns h o w nt op r o m o t ec e l ls u r v i v a lo fh e p a t o c y t e sd u r i n g
development, sustaining the transcription of antioxidant
genes and protecting embryonic hepatocytes from TNF-
mediated apoptosis [124]. Moreover, NRF-1 has been shown
to be induced under prooxidant conditions and to promote
the transcription of mitochondrial transcription factor A
(Tfam), required for mitochondrial DNA transcription and
replication [123]. Hypoxia is another clear example of cell
signaling mediated by ROS. Hypoxia is a clinical relevant
event both in liver ischemia/reperfusion injury and in hep-
atocellular carcinoma development. It leads to an increase
in production of H2O2 from mitochondrial complex III,
thus creating a cytosolic signal that stabilizes the hypoxia
inducible transcription factors HIF-1 [27, 127]. Moreover,
during hypoxia ROS activates AMPK, which in turn phos-
phorylates Na/K ATPase (in order to promote its endocy-
tosis) and mTOR (in order to decrease protein translation),
thuscontributingtoenergyconservation [128,129].Inaddi-
tion, hypoxia-induced mitochondrial ROS enhance the DNA
binding of NF-κB through a redox-dependent mechanism
involving the mitochondrial glutathione (mGSH) pool in
cancer cells, including hepatoma cell lines [130, 131]. In
this context, mGSH regulates the intensity of ROS diﬀusion
in the cytoplasm, allowing activation of the c-Src kinase,
with subsequent phosphorylation of the inhibitory subunit
IκB, activation of NF-κB and promotion of cancer cell
survival [127, 130]. The liver is one of the organs with
the highest content of GSH and mGSH plays a central role
in regulating both in antioxidant defense against excessive
ROS production and in regulation of ROS signaling in liver
physiology and pathology [130]. Alcohol consumption has
been shown to sensitize hepatocytes to TNF because of
mGSH depletion through impaired transport of GSH to
mitochondria [132]. Interestingly, GSH transport impair-
ment and TNF sensitization correlate with free choles-
terol accumulation in mitochondrial membranes and seem
to be a common pro-inﬂammatory mechanism in both
alcoholic and nonalcoholic steatohepatitis [133]. Similar
a l t e r a t i o n si nm G S Hr e g u l a t i o nh a v eb e e nr e p o r t e di nl i v e r
cirrhosis, in particular in an experimental model of sec-
ondary biliary cirrhosis in rats induced by bile-duct ligation
[134, 135].
During the past decade, a new family of enzymes,
the nicotinamide-adenine-dinucleotide- (NAD-) dependent
protein deacetylases named sirtuins, has been described
to contribute to extended lifespan many animal models,
including mammals [136]. Interestingly of the six mam-
malian sirtuins, three (SIRT3, 4, and 5) are expressed in
themitochondriawheretheymediatephysiologicadaptation
to reduced energy consumption [137]. In the liver, SIRT4
activity was shown to decline during calorie restriction,
allowing the consumption of glutamine as a fuel source for
glucose synthesis. Moreover, SIRT4 depletion increased fatty
acid oxidation [138]. Mitochondrial sirtuins could be also
interesting targets in the regulation of ammonia production
and disposal. Nakagawa et al. [139] have shown that the
sirtuin SIRT5 activates CPS1, which we mentioned before
as the ﬁrst enzyme in the urea cycle. In mice, NAD in liver
mitochondria increases during fasting, thereby triggering
SIRT5-mediated deacetylation of CPS1 and adaptation to
increaseinaminoacidcatabolism.ThesedataindicateSIRT5
also has an emerging role in the metabolic adaptation to
fasting, high protein diet and calorie restriction. Finally,
recent ﬁndings correlate SIRT3 to the production of ROS.
In particular, SIRT3−/− cells produce increased levels of ROS
and have concomitantly a reduced ATP production [11, 12,
140]. These results suggest that SIRT3-mediated deacetyla-
tion of electron transport chain may render OXPHOS more
eﬃcient[137].Moreover,SIRT3maydeacetylateandactivate
the antioxidant enzyme mitochondrial superoxide dismutase
(SOD2) and the isocitrate dehydrogenase 2, which generates
NADPH for the glutathione synthesis, in mice [141–143].Biochemistry Research International 11
The sirtuins’ antiaging role and their ability of controlling
energy metabolism make them interesting target in cancer
and metabolic diseases. Interestingly, in a mouse model of
metabolic syndrome-associated liver cancer, overexpression
of SIRT1 reduced the susceptibility to liver cancer and
improved hepatic protection from both DNA damage and
metabolic damage [136]. However, recent studies showed
that SIRT1 was upregulated in HCC and it has a role in
telomere maintenance [144, 145]. Downregulation of SIRT1
suppressed proliferation of HCC cells and induced cellular
senescence or apoptosis [144]. Finally, many recent papers
show a possible synergic action of cytosolic and mitochon-
drial sirtuins in regulating glucose and lipid metabolism in
the liver [138, 140, 146–148]. SIRT1 has been shown to
regulate hepatic glucose and lipid metabolism by activating
AMPK and by inducing gluconeogenic genes via activation
of PGC-1 alpha in hepatic cell and mouse liver [146, 147].
Interestingly, SIRT1 did not regulate the PGC-1 alpha eﬀects
on mitochondrial biogenesis. The mitochondrial SIRT3 was
shown to positively modulate fatty acid oxidation and
ATP production, in particular deacetylating the long-chain
acyl-CoA dehydrogenase and Complex I of the electron
transport chain [140, 148]. Finally, in a recent paper, high-
fat diet induced a decrease of hepatic SIRT3, hyperacety-
lation of mitochondrial proteins and fatty liver in mice
[149].
Altogether, the studies reviewed show that mitochon-
dria are much more dynamic organelles than considered
traditionally. They are key organelles in the integration
and adaptation to external stimuli, such as changing com-
position of diet (i.e., calorie restriction versus high fat
diet), hypoxia, cold exposure, or physical exercise [150].
Mitochondrial homeostasis is a highly controlled process
balancing organelle biogenesis and degradation (essentially
by autophagy/mitophagy) and an alteration of this balance
may bring to organelle dysfunction, contributing to the
development of liver chronic diseases.
5. Conclusions
The liver is one of the organs richest in mitochondria. Hep-
atic mitochondria have unique features compared to other
organs’ mitochondria, since they are the hub that integrates
hepatic metabolism of carbohydrates, lipids, and proteins.
Thus, correct functioning of hepatic mitochondria is essen-
tial not only to prevent liver disease, such as NAFLD, but
also to avoid systemic diseases, such as ammonia-induced
hepatic encephalopathy. Mitochondria are also essential in
hepatocyte survival as mediator of apoptosis and necrosis.
H e p a t o c y t ec e l ld e a t hi si n v o l v e di nm o s tl i v e rp a t h o l o g i e s ,
such as alcoholic and nonalcoholic steatohepatitis, viral
hepatitis, liver ﬁbrosis, and carcinogenesis. Hepatocytes
have developed diﬀerent mechanisms to keep mitochondrial
integrity or to prevent the eﬀects of mitochondrial lesions, in
particularregulatingorganellebiogenesisanddegradation.A
better knowledge of the mechanisms and pathways involved
inmitochondriahomeostasisshouldimprovepreventiveand
therapeutic strategies for liver diseases.
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